The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
76 of 180 long COVID-associated genes also linked to ME
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Subscribe To Our Newsletter & Stay Updated